Why? How are telaprevir and boceprevir going to successfully fend off competitive HCV PIs with potentially significant advantages in dosing, potency, safety, and pan-genotypic coverage? I realize the 2nd and 3rd gen HCV PIs still have a ways to go in the clinic to realize these advantages, but they represent significant threats to telaprevir and boceprevir in the not-too-distant future.
Market Data 
Markets 
AI
